Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III induction therapy with RO7790121 in moderately to severely active ulcerative colitis
ChiCTR2500108288Phase 3Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing RO7790121 with Placebo (2 arms). Primary endpoint: Clinical remission at Week 12. Started Aug 2025; status: recruiting.
02
Drugs
afimkibart
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on ChiCTR2500108288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108288.